Dr Narasa Raju Kavalipati

Dr Narasa Raju Kavalipati is a distinguished Cardiologist based at Apollo Hospitals Hyderguda. With an impressive 21 years of experience in the medical field, he has dedicated his career to providing exceptional healthcare services to patients. He holds DM(Cardiology), MD (General Medicine), MBBS, showcasing his extensive training and commitment to medical excellence. He is proficient in multiple languages, ensuring effective communication with a diverse range of patients.

He is known for his patient-centric approach, emphasizing the importance of understanding each patient’s unique needs and medical history. He expertise encompasses a wide range of conditions related to Cardiologist, enabling he to deliver precise diagnoses and treatments. He ensures that patients receive care tailored to their individual health requirements.

In his practice, Dr Narasa Raju Kavalipati goes beyond treatments by educating patients about their health conditions. This empowers individuals to take active roles in managing their health and making informed decisions. By fostering a supportive and understanding environment, he builds trust and ensures long-term health management strategies for patients.

Dedicated to staying updated with advancements in his field, Dr Narasa Raju Kavalipati actively collaborates with other healthcare professionals to provide comprehensive care. He commitment to improving health outcomes continues to leave a lasting impact on the lives of his patients, solidifying his reputation as a trusted name in Cardiologist.

• Worked as Senior interventional cardiologist at   Yashoda Super Specialty Hospitals & Apollo Hospitals Hyderabad.
• Ex Clinical Director Sunshine Heart Institute, Secunderabad
• Present assignment Director Cath Lab & Sr Interventional Cardiologist Apollo Hospital, Hyderguda, Hyderabad
•  Involved as a Principal Investigator in two international multi-centre clinical trials
• 1“A Double-Blind, randomized, Placebo-Controlled, Multicentre study to access the efficacy and safety of Darbepoetin alpha Treatment on Morbidity and Mortality in Heart Failure (HF) subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia”
•   The RED-HF Clinical Trial
• 2 “A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to evaluate the efficacy and safety of Rivaroxaban in subjects with a recent Acute Coronary Syndrome”
• The ATLAS ACS 2 TIMI 51 Trial
• Active core committee member Lipid association of India
• President Elect of CSI Telangana chapter
• With a passion for teaching, actively involved in teaching DNB cardiology fellows and budding interventional cardiologists.